Get news updates from AACRMeetingNews.org
Subscribe below to get email updates from AACRMeetingNews.org
Five leading researchers discussed new concepts in drug discovery, engineering, and delivery on the final day of the Annual Meeting. Evan A. Scott, PhD, reviewed the use of targeted nanocarriers for cell-selective cancer therapy.
Three experts discussed the evolution of phase I trials during an Annual Meeting symposium on Tuesday, April 18. “We must recognize that forward- and reverse-translation are complementary and phase I is the place to do it. The old linear model of moving forward and failing later is not serving us or our patients,” said Shivaani Kummar, MD.
An expert panel, including session co-chairs Luis A. Diaz, MD, and Folakemi Odedina, PhD, discussed strategies to overcome disparities in oncology clinical trials during the Minorities in Cancer Research Scientific Symposium.
A panel of physician-scientists from the U.S. and sub-Saharan Africa discussed the challenges of global cancer care and opportunities to improve outcomes in lower- and middle-income countries during a symposium on the final day of the Annual Meeting. Sharmila Anandasabapathy, MD, moderated the session.
Three technology innovators, including session chair Tina Hernandez-Boussard, PhD, MPH, discussed how data-driven learning systems can be applied to different cancers to improve patient symptoms, outcomes, and overall care during an Annual Meeting symposium.
During the Annual Meeting’s third clinical trials plenary session, researchers reported promising results from four early-phase trials. Samer A. Srour, MD, reported results from the first-in-human trial of allogeneic CAR T therapy targeting CD70 expressed in metastatic renal cell carcinoma.
In the final clinical trials plenary session of the Annual Meeting, researchers highlighted more promising studies. Jordi Rodon, MD, PhD, reported results from the FIGHT-207 trial of pemigatinib, which showed antitumor activity in multiple pretreated solid tumors with FGFR alterations.
Annual Meeting Program Committee Chair Robert H. Vonderheide, MD, DPhil, shares a few highlights from Wednesday’s schedule to help plan your day.
During a unique Annual Meeting session, National Cancer Institute Director Monica M. Bertagnolli, MD (pictured), sat down with AACR President Lisa M. Coussens, PhD, FAACR, to discuss the NCI’s goals for the Cancer Moonshot initiative and the recently released National Cancer Plan.
To mark the 25th anniversary of trastuzumab, H. Michael Shepard, PhD, and three other scientists who were involved in the discoveries that led to the development of the drug discussed how those discoveries continue to inform cancer care and research.